Viridian Therapeutics (NASDAQ:VRDN) focuses on advancing innovative treatments for patients battling serious diseases, with a significant emphasis on thyroid eye disease (TED) and other autoimmune and fibrotic diseases. The company operates with the mission to transform the lives of those afflicted by these conditions through groundbreaking therapies and treatments. By diving deep into research and development, Viridian aims to address the unmet medical needs of patients worldwide. Its projects range from early-stage investigation to near-market therapies, highlighting a commitment to scientific excellence and patient care. Objectives of Viridian include spearheading the development of novel treatments, ensuring accessibility to these innovations, and continuously exploring new therapeutic areas to expand their impact on healthcare.